{
  "timeline": [
    {
      "year": 2015,
      "trials": 19,
      "cumulative": 19
    },
    {
      "year": 2016,
      "trials": 21,
      "cumulative": 40
    },
    {
      "year": 2017,
      "trials": 24,
      "cumulative": 64
    },
    {
      "year": 2018,
      "trials": 63,
      "cumulative": 127
    },
    {
      "year": 2019,
      "trials": 62,
      "cumulative": 189
    },
    {
      "year": 2020,
      "trials": 59,
      "cumulative": 248
    },
    {
      "year": 2021,
      "trials": 119,
      "cumulative": 367
    },
    {
      "year": 2022,
      "trials": 76,
      "cumulative": 443
    },
    {
      "year": 2023,
      "trials": 88,
      "cumulative": 531
    },
    {
      "year": 2024,
      "trials": 100,
      "cumulative": 631
    },
    {
      "year": 2025,
      "trials": 76,
      "cumulative": 707
    }
  ],
  "milestones": [
    {
      "year": 2016,
      "title": "First Human Trial",
      "description": "First CRISPR-Cas9 clinical trial in humans (China)",
      "icon": "\ud83e\uddec"
    },
    {
      "year": 2019,
      "title": "CTX001 Success",
      "description": "First sickle cell patient treated with success",
      "icon": "\ud83e\ude78"
    },
    {
      "year": 2020,
      "title": "Nobel Prize",
      "description": "Doudna & Charpentier win Chemistry Nobel",
      "icon": "\ud83c\udfc6"
    },
    {
      "year": 2023,
      "title": "FDA Approval",
      "description": "Casgevy approved for Sickle Cell Disease",
      "icon": "\u2705"
    }
  ]
}